Navigation Links
Sinovac Reports Unaudited First Quarter 2010 Financial Results
Date:5/13/2010

ry. Net income for the same period of 2009 included $126,000 of interest and financing expenses, $93,000 of interest and other income, and $482,000 of income tax expenses. Net loss attributable to shareholders for first quarter of 2010 was $307,000, or $0.01 loss per diluted share, as compared to net income attributable to shareholders of $25,000, or $0.00 per diluted share, in the same period of 2009.

As of March 31, 2010, Sinovac's cash and cash equivalents totaled $118.9 million, compared to $75.0 million as of December 31, 2009. The increase in cash and cash equivalents primarily reflects the contribution of approximately $62.0 million in net proceeds from the public offering of common shares, which closed in February 2010.

Recent Developments

Sinovac's 30%-owned joint venture, Sinovac Dalian, submitted an application to the SFDA to commence human clinical trials for its mumps vaccine. The proprietary mumps vaccine developed by Sinovac Dalian represents not only the first live attenuated vaccine for which Sinovac has filed a clinical trial application, but also the first candidate from the joint venture's pipeline for which a clinical trial application has been submitted to and accepted by the SFDA since the formation of the joint venture in January 2010.

After receiving regulatory approval from China's State Administration of Foreign Exchange, Sinovac Biotech, through it
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sinovac to Host Conference Call to Report First Quarter 2010 Financial Results
2. Sinovac Announces Upsizing and Pricing of Common Share Offering
3. Sinovac Files Clinical Trial Application with SFDA for Vaccine Against Hand, Foot, and Mouth Disease
4. Sinovacs CEO Weidong Yin Presented with Annual Innovation Award by China Central Television
5. Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities
6. Sinovac Reports Unaudited Third Quarter 2009 Financial Results
7. Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government
8. Sinovac Receives Certificate of Approval to Distribute Panflu (H5N1) Vaccine in Hong Kong
9. Sinovac to Present at 2009 UBS Global Life Sciences Conference
10. Sinovac Obtains Lot Release Certificate for Its First Batch of H1N1 Vaccine
11. Sinovac Obtains Initial Order of H1N1 Vaccine from Chinese Central Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Sinovac Biotech Ltd. ... products in China , today announced that ... quarter ended June 30, 2014, after market close on Thursday, ... call prior to the market opening on Friday, August 15, ... 8:00 p.m. China Standard Time) to review the Company,s financial ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... Calif. , July 24, 2014  ECC West ... Denver, Colorado with University College Hospital (UCH) ... a development project to finance, design, construct, and operate ... Nigeria . Under the first of ... prepare scoping documents and funding applications. UCH Ibadan intends ...
(Date:7/24/2014)... to materialise. Yet, scientists are making progress in ... One such approach relies on quantum dotsa kind ... electric field. A new study demonstrates that changing ... (TQDs) with electrical impulses can help better control ... be used as quantum information units, which would ...
Breaking Biology Technology:Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... Covance Inc. (NYSE:,CVD) today announced that it will ... Tuesday, May 13, 2008 at 10:30 am ET. Investors ... http://www.covance.com . In order to,register and download any necessary ... headquarters in Princeton, New Jersey, is one of the,world,s ...
... SAN CLEMENTE, Calif., May 12 USGI Medical, ... that the company has,licensed its incisionless surgery technology ... robotics applications. Financial terms of the deal,were not ... and clinical development,including their intellectual property," said Gary ...
... Bulletin Board: NURX pre split, NUXP post split) today ... split became,effective. The Company has been informed by the ... connection with the reverse stock,split, its trading symbol has ... split will reduce the number of issued and,outstanding shares ...
Cached Biology Technology:USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 2USGI Medical Licenses Incisionless Surgery Technology to Intuitive Surgical 3NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect 2
(Date:7/25/2014)... (NRG1) is a pleiotropic factor characterized by the ... of exons that confer to the protein deeply ... both the myelination occurring during development and the ... nerve: axon degeneration, axon regrowth, remyelination and target ... have discovered that the soluble NRG1 upregulation observed ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... diet with large amounts of vegetables and fish gives a ... to be published by the Sahlgrenska Academy at the University ... that a Mediterranean diet, based on a high consumption of ... such as meat and milk, leads to better health., ...
... WEST LAFAYETTE, Ind. - Bacteria are able to ... disease - by manipulating a natural cellular process. , ... revealed how a pair of proteins from the bacteria Legionella ... order to divert raw materials within the cell for use in ...
... project from LIFE the Faculty of Life Sciences at ... a different growth pattern than non-breastfed children. Breastfeeding lowers the ... blood, which means that growth is slightly slower. This is ... in life. The PhD project is part of ...
Cached Biology News:Purdue scientists reveal how bacteria build homes inside healthy cells 2Purdue scientists reveal how bacteria build homes inside healthy cells 3Breastfeeding promotes healthy growth 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Reactivity: Human...
... Transformation Kit is designed for rapid ... Advantages over commonly used transformation procedures ... methods include:- Cells can be made competent ... cell preparation and transformation solutions are ...
...
Biology Products: